Merck & Co Inc
MRKToday
-1.32%
5 Days
+1.33%
1 Month
+17.11%
6 Months
+31.73%
Year to Date
+44.91%
1 Year
+83.40%
Recent
Analysis
Moderna Inc Stock (MRNA) Moved Down by 5.69% on Aug 27: Key Drivers Unveiled
• Moderna announced a proposed two billion dollar convertible senior notes private placement. • The pullback followed profit-taking after positive Phase 3 clinical trial developments. • Annual revenue stands at $1.94 billion alongside a net profit of $-2.82 billion.
Novo Nordisk A/S Stock (NVO) Moved Down by 3.32% on Aug 26: Drivers Behind the Movement
• Novo Nordisk faced downside pressure due to margin compression and pricing dynamics. • Intense competition from rival therapies heightened sensitivity to market share trends. • The stock reported an annual revenue of $46.70B and net profit of $15.48B.
Summit Therapeutics Inc Stock (SMMT) Moved Up by 8.95% on Aug 26: Drivers Behind the Movement
• Summit Therapeutics shares rose following positive Phase 3 trial results for ivonescimab. • The HARMONi-GI1 study met its primary overall survival endpoint in biliary tract cancer. • Summit reports zero annual revenue and a net loss of $1.08 billion.
Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement
• Eli Lilly shares experienced downward pressure due to investor profit-taking after recent gains. • Growth concerns persist over corporate and commercial health plan reimbursement for obesity treatments. • The company maintains a strong competitive moat and structurally intact long-term growth outlook.
Moderna Inc Stock (MRNA) Opened Down by 5.46% on Aug 26: Drivers Behind the Movement
• Moderna faced volatility and profit-taking after a multi-session rally. • Investors await detailed clinical data and commercial manufacturing cost assessments. • Technical indicators show a MACD buy signal and neutral RSI.
Novo Nordisk A/S Stock (NVO) Closed Up by 3.71% on Aug 25: A Full Analysis
• Wall Street raised Novo Nordisk price targets and long-term financial forecasts. • Strong GLP-1 therapy adoption and share buybacks bolster market confidence. • The company reports $46.70B in annual revenue and $15.48B in net profit.
Merck & Co Inc's Score
Media Coverage
Analyst Rating
Merck & Co Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Merck & Co Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.52% |
| BlackRock Institutional Trust Company, N.A. | 5.51% |
| State Street Investment Management (US) | 4.86% |
| Wellington Management Company, LLP | 3.50% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 42.43% |
| Investment Advisor/Hedge Fund | 27.18% |
| Research Firm | 3.05% |
| Pension Fund | 2.68% |
Related Instruments
Popular Instruments
